Trial · NCT06548100
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
NCT06548100, Phase 3, Completed, Regeneron Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD). Trials, record NCT06548100. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06548100
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
- NCT number
- NCT06548100
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 9 participants, actual
- Lead sponsor
- Regeneron Pharmaceuticals
- Conditions
- Generalized Lipodystrophy
- Interventions
- mibavademab
- First posted
- 2024-08-12
- Last updated
- 2026-07-29
- Other registries' IDs
- eudract:2026-000121-16
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of treatment-emergent adverse events (TEAEs) | Up to week 68 | |
| Primary | Severity of TEAEs | Up to week 68 | |
| Secondary | Change in Hemoglobin A1c (HbA1c) | Baseline, week 20 and week 52 | |
| Secondary | Occurrence of HbA1c <7% | Week 20 and week 52 | |
| Secondary | Occurrence of HbA1c <6.5% | Week 20 and week 52 | |
| Secondary | Occurrence of requiring therapy with insulin in participants treated with mibavademab | Week 20 and week 52 | |
| Secondary | Change in total insulin dose | Baseline, week 20 and week 52 | |
| Secondary | Change in fasting plasma glucose | Baseline, week 20 and week 52 | |
| Secondary | Percent change in fasting triglycerides | Baseline, week 20 and week 52 | |
| Secondary | Occurrence of fasting triglycerides <500 mg/dL in participants treated with mibavademab | Baseline, week 20 and week 52 |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06548100
GET https://conductscience.org/api/trials/v1/NCT06548100/registered